Species-dependent hepatic and intestinal metabolism of selective oestrogen receptor degrader LSZ102 by sulphation and glucuronidation

References

• Falany CN. 1997. Enzymology of human cytosolic sulfotransferases. FASEB J. 11(4):206–216.
   PubMed Web of Science ®Google Scholar
• Falany JL, Pilloff DE, Leyh TS, Falany CN. 2006. Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos. 34(3):361–368.
   PubMed Web of Science ®Google Scholar
• FDA. 2016. Guidance for industry: safety testing of drug metabolites. Silver Spring, MD: FDA.
   Google Scholar
• Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, McManus ME. 2006. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci. 90(1):5–22.
   PubMed Web of Science ®Google Scholar
• Hamilton RA, Garnett WR, Kline BJ. 1981. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther. 29(3):408–413.
   PubMed Web of Science ®Google Scholar
• Hui Y, Luo L, Zhang L, Kurogi K, Zhou C, Sakakibara Y, Suiko M, Liu MC. 2015. Sulfation of afimoxifene, endoxifen, raloxifene, and fulvestrant by the human cytosolic sulfotransferases (SULTs): A systematic analysis. J Pharmacol Sci. 128(3):144–149.
   PubMed Web of Science ®Google Scholar
• ICH. 2009. Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). Geneva, Switzerland: ICH.
   Google Scholar
• ICH. 2010. S9 nonclinical evaluation for anticancer pharmaceuticals. Geneva, Switzerland: ICH.
   Google Scholar
• Jhaveri K, Juric D, Yap YS, Cresta S, Layman RM, Duhoux FP, Terret C, Takahashi S, Huober J, Kundamal N, et al. 2021. A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor-positive breast cancer. Clin Cancer Res. 27:5760–5770.
   PubMed Web of Science ®Google Scholar
• Kemp DC, Fan PW, Stevens JC. 2002. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos. 30(6):694–700.
   PubMed Web of Science ®Google Scholar
• King CD, Rios GR, Green MD, Tephly TR. 2000. UDP-glucuronosyltransferases. Curr Drug Metab. 1(2):143–161.
   PubMed Web of Science ®Google Scholar
• Ladumor MK, Bhatt DK, Gaedigk A, Sharma S, Thakur A, Pearce RE, Leeder JS, Bolger MB, Singh S, Prasad B. 2019. Ontogeny of hepatic sulfotransferases and prediction of age-dependent fractional contribution of sulfation in acetaminophen metabolism. Drug Metab Dispos. 47(8):818–831.
   PubMed Web of Science ®Google Scholar
• Lin W, Heimbach T, Harsch A, Tse A, Ji Y. 2021. Model informed drug development of LSZ102 to predict human efficacious dose and food effect. American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther. 109:S5–S88.
   Google Scholar
• Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, Warram J. 1985. The metabolism of estradiol; oral compared to intravenous administration. J Steroid Biochem. 23(6):1065–1070.
   PubMedGoogle Scholar
• Martignoni M, Groothuis GM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2(6):875–894.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Konno Y, Hashimoto T, Nagai M, Taguchi T, Satsukawa M, Yamashita S. 2015. Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats. Pharm Res. 32(2):604–616.
   PubMed Web of Science ®Google Scholar
• Mizuma T. 2009. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm. 378(1–2):140–141.
   PubMed Web of Science ®Google Scholar
• Riches Z, Stanley EL, Bloomer JC, Coughtrie MW. 2009. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT “pie”. Drug Metab Dispos. 37(11):2255–2261.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Harrison M. 2004. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer 90( 1):S7–S10.
   PubMed Web of Science ®Google Scholar
• Rowland A, Miners JO, Mackenzie PI. 2013. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 45(6):1121–1132.
   PubMed Web of Science ®Google Scholar
• Sawamura R, Okudaira N, Watanabe K, Murai T, Kobayashi Y, Tachibana M, Ohnuki T, Masuda K, Honma H, Kurihara A, et al. 2010. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos. 38(10):1857–1864.
   PubMed Web of Science ®Google Scholar
• Suiko M, Kurogi K, Hashiguchi T, Sakakibara Y, Liu MC. 2017. Updated perspectives on the cytosolic sulfotransferases (SULTs) and SULT-mediated sulfation. Biosci Biotechnol Biochem. 81(1):63–72.
   PubMed Web of Science ®Google Scholar
• Tria GS, Abrams T, Baird J, Burks HE, Firestone B, Gaither LA, Hamann LG, He G, Kirby CA, Kim S, et al. 2018. Discovery of LSZ102, a potent, orally bioavailable selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive breast cancer. J Med Chem. 61(7):2837–2864.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan JB, Walle T. 2002. Glucuronidation and sulfation of the tea flavonoid (-)-epicatechin by the human and rat enzymes. Drug Metab Dispos. 30(8):897–903.
   PubMed Web of Science ®Google Scholar
• Walles M, Brown AP, Zimmerlin A, End P. 2020. New perspectives on drug-induced liver injury risk assessment of acyl glucuronides. Chem Res Toxicol. 33(7):1551–1560.
   PubMed Web of Science ®Google Scholar
• Wang Q, Jia R, Ye C, Garcia M, Li J, Hidalgo IJ. 2005. Glucuronidation and sulfation of 7-hydroxycoumarin in liver matrices from human, dog, monkey, rat, and mouse. In Vitro Cell Dev Biol Anim. 41(3–4):97–103.
   PubMed Web of Science ®Google Scholar
• Wu B, Kulkarni K, Basu S, Zhang S, Hu M. 2011. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci. 100(9):3655–3681.
   PubMed Web of Science ®Google Scholar